JPRN-UMIN000025771已完成未知
Effects of Long-term Dapagliflozin Treatment on Hemorheology, Leukocyte Activation and Oxidative Stress - Effects of Long-term Dapagliflozin Treatment on Hemorheology, Leukocyte Activation and Oxidative Stress
Dokkyo Medical University Nikko Medical Center Department of Clinical Study Support Center0 个研究点目标入组 90 人开始时间: 2017年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
Hepatocrit was increased by about 2% after 16 weeks of dosage of depagliflosin in type 2 diabetes patients, but proved to be inferior in terms of blood fluidity compared to the conventional treatment group
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(a) Patients with type 1 diabetes mellitus (b) Patients with a medical history of hypersensitivity to any of the ingredients of dapagliflozin (c) Patients with severe ketosis or diabetic coma or pre-coma (d) Patients who have severe infection, are pre- or postoperative, or have sustained serious trauma (e) Patients with severe impaired liver function (f) Patients who are susceptible to dehydration (g) Patients with urinary tract infection or genital infection (h) Patients with a history of cerebrovascular disease within the last 3 months (i) Women who are pregnant or breastfeeding or who may be pregnant (j) Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 mL (k) Patients on warfarin or a novel oral anticoagulant (NOAC) (dabigatran, rivaroxaban, edoxaban, or apixaban) (l) Current smokers (m) Patients otherwise deemed to be unsuitable for the clinical study by investigators
研究者
相似试验
已完成
不适用
Effects of Long-term Dapagliflozin Treatment on Hemorheology, Leukocyte Activation and Oxidative StressType 2 diabetes mellitusJPRN-jRCTs071180044Yasu Takanori90
已完成
4 期
Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic PatientsType 2 Diabetes MellitusNCT02751398Yonsei University60
招募中
2 期
A single-site study of the effectiveness of Dapagliflozin for diabetic patients admitted to the intensive care unitMetabolic and Endocrine - DiabetesDiabetesACTRN12621001102864Austin Health40
已完成
4 期
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver diseaseon-alcoholic fatty liver diseaseDiabetes patientNAFLDDM type IISGLT2 inhibitorInsulin resistanceFatty liverTCTR20170511001The Faculty of Medicine endownment Fund38
招募中
4 期
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLDType2 Diabetes MellitusNonalcoholic Fatty Liver DiseaseNCT06449833Zhujiang Hospital100